PLS and shape-based similarity analysis of maleimides-GSK-3 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 4, 2014, Pages 599-610

  Crisan, Luminita ^a   Pacureanu, Liliana ^a   Avram, Sorin ^a   Bora, Alina ^a   Avram, Speranta ^b   Kurunczi, Ludovic ^c  

^a ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Pose prediction; QSAR; Rank correlation; ROCS

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MALEIMIDE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; MALEIMIDE;

ARTICLE; DRUG BINDING SITE; DRUG STRUCTURE; ELECTRON DIFFRACTION; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROJECTION TO LATENT STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAPID OVERLAY OF CHEMICAL STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DATABASE; METABOLISM; SYNTHESIS;

DATABASES, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALEIMIDES; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904313352     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.833196     Document Type: Article

References (82)

1. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23:329-36.
2. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;356:1-16.
3. Doble BW, Woodgett JR. GSK-3: Tricks of the trade for a multitasking kinase. J Cell Sci 2003;116:1175-86.
4. Hong M, Chen DC, Klein PS, Lee VM. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997;272:25326-32.
5. Nikolakaki E, Coffer PJ, Hemelsoet R, et al. Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene 1993;8:833-40.
6. Welsh GI, Miller CM, Loughlin AJ, et al. Regulation of eukaryotic initiation factor eIF2B: Glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 1998;421:125-30.
7. Wauwe JV, Haefner B. Glycogen synthase kinase-3 as drug target: From wallflower to center of attention. Drug News Perspect 2003;16: 557-65.
8. Kulkarni NH, Wei T, Kumar A, et al. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem 2007;102:1504-18.
9. Cross DAE, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;37:785-9.
10. Ross SE, Erickson RL, Hemati N, MacDougald OA. Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 1999;19:8433-41.
11. Cohen P, Goedert M. GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-87.
12. Smith DG, Buffet M, Fenwick AE, et al. 3-Anilino-4-Arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 2001;11:635-9.
13. Polychronopoulos, P Magiatis P, Skaltsounis AL, et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 2004;47:935-46.
14. Kunick C, Lauenroth K, Leost M, et al. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3. Bioorg Med Chem Lett 2004;14:413-16.
15. Ibrahim N, Mouawad L, Legraverend M. Novel 8-Arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem 2010;45: 3389-93.
16. Chen PC, Gaisina IN, El-Khodor BF, et al. Identification of a maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitor, BIP-135, that prolongs the median survival time of D7 SMA KO mouse model of spinal muscular atrophy. ACS Chem Neurosci 2012;3:5-11.
17. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
18. Cross DAE, Cubert AA, Chalmers KA, et al. Selective smallmolecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001;77:94-102.
19. Culbert AA, Brown MJ, Frame S, et al. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 2001;507:288-94.
20. Eriksson L, Jaworska J, Worth A, et al. Methods for reliability, uncertainty assessment, and applicability evaluations of regression based and classification QSARs. Environ Health Perspect 2003;111: 1361-75.
21. Tropsha A, Gramatica P, Gombar VK. The importance of being Earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 2003;22: 69-77.
22. Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des 2007;13:3494-504.
23. Broccatelli F, Mannhold R, Moriconi A, et al. QSAR modeling and data mining link torsades De pointes risk to the interplay of extent of metabolism, active transport, and hERG liability. Mol Pharmaceutics 2012;9:2290-301.
24. Ripphausen P, Nisius B, Bajorath J. Quo vadis virtual screening?. A comprehensive survey of prospective applications. J Med Chem 2010;53:8461-7.
25. Rush TS, Grant JA, Mosyak L, Nicholls A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein- protein interaction. J Med Chem 2005;48:1489-95.
26. Tuccinardi T, Ortore G, Santos AM, et al. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors. J Chem Inf Model 2009;49:1715-24.
27. Sutherland JJ, Nandigam RK, Erickson JA, Vieth M. Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy. J Chem Inf Model 2007;47:2293-302.
28. Sivaprakasam P, Aihua Xie A, Doerksen RJ. Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-Anilino-4-phenylmaleimides. Bioorg Med Chem 2006;14:8210-18.
29. Katritzky AR, Pacureanu LM, Dobchev DA, et al. QSAR modeling of the inhibition of glycogen synthase kinase-3. Bioorg Med Chem 2006;14:4987-5002.
30. Sivaprakasam P, Daga PR, Xie A, Doerksen RJ. Glycogen synthase kinase-3 inhibition by 3-Anilino-4-phenylmaleimides: Insights from 3D-QSAR and docking. J Comput Aided Mol Des 2009;23:113-27.
31. Lescot E, Bureau R, Sopkova-de Oliveira Santos J, et al. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno(2,3-b)pyrrolizinone derivative, a new potential lead for GSK-3beta ligands. J Chem Inf Model 2005;45:708-15.
32. Dessalew N, Bharatam PV. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: An insight into the criteria for selectivity. Eur J Med Chem 2007;42: 1014-27.
33. Engler TA, Malhotra S, Burkholder TP, et al. The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg Med Chem Lett 2005;15:899-903.
34. MarvinSketch. 2010. version 5.4, ChemAxon, Available from: Http://www.chemaxon.com [last accessed 16 Feb 2011]
35. HyperChem 7.52 release for Windows, HyperCube, Inc. Gainesville, FL. Available from: Http://www.hyper.com [last accessed 20 Dec 2012]
36. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 1985;107:3902-9.
37. Dragon - A software for the calculation of molecular descriptors, version 3.0; 2003. Available from: Http://www.talete.mi.it [last accessed 16 Jan 2013]
38. Nathan Mantel. The detection approach of disease clustering regression. Cancer Res 1967;27:209-20.
39. Stephane Dray, Anne-Beatrice Dufour. The ade4 Package: Implementing the duality diagram for ecologists. J Statis Software 2007; 22:1-20.
40. R: A language and environment for statistical computing, R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2012, ISBN 3-900051-07-0, Available from: Http://www.R-project. org/[last accessed 7 Mar 2013]
41. Wold S, Johansson E, Cocchi M. PLS- partial least-square projection in latent structures. In: Kubinyi H, ed. 3D QSAR in drug design; theory, methods, and applications. Leiden: ESCOM Holland; 1993:523-50.
42. Eriksson L, Gottfries J, Johansson E, Wold S. Time-resolved QSAR: An approach to PLS modelling of three-way biological data. Chemometr Intell Lab Syst 2004;73:73-84.
43. SIMCA P, version 9.0, Umetrics AB: Umea, Sweden. Available from: Http://www.umetrics.com [last accessed 29 Jan 2013]
44. Pearson K. On lines and planes of closest fit to systems of points in space. Philos Magazine 1901;2:559-72.
45. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Multi- And megavariate data analysis: Principles and applications. Umea: Umetrics AB, Sweden 2001;92-97:489-91.
46. Golbraikh A, Tropsha A. Beware of q2!. J Mol Graphics Model 2002;20:269-76.
47. Golbraikh A, Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comp Aided Mol Des 2002;16:357-69.
48. Golbraikh A, Shen M, Xiao Z, et al. Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 2003;17:241-53.
49. OpenEye Scientific Software. 2008. OMEGA, version 2.3.2. OpenEye Scientific Software, Santa Fe NM 87508. Available from: Http://www.eyesopen.com [last accessed 10 Jan 2013]
50. Hawkins PCD, Skillman AG, Warren GL, et al. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and Cambridge Structural Database. J Chem Inf Model 2010;50:572-84.
51. Perola E, Charifson PS. Conformational analysis of drug-like molecules bound to proteins: An extensive study of ligand reorganization upon binding. J Med Chem 2004;47:2499-510.
52. Hawkins PCD, Nicholls A. Conformer generation with OMEGA: Learning from the data set and the analysis of failures. J Chem Inf Model 2012;52:2919-36.
53. Boström J, Greenwood JR, Gottfries J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J Mol Graph Model 2003;21:449-62.
54. OpenEye Scientific Software. 2010. ROCS version 3.1.0 Santa Fe NM 87508. Available from: Http://www.eyesopen.com [last accessed 12 Feb 2013]
55. RCSB Protein Data Bank. Available from: Http://www.rcsb.org/pdb/home/home.do [last accessed 15 Dec 2012]
56. Hawkins PCD, Skillman AG, Nicholls A. Comparison of shapematching and docking as virtual screening tools. J Med Chem 2007; 50:74-82.
57. Kim S, Bolton EE, Bryant SH. PubChem3D: Shape compatibility filtering using molecular shape quadrupoles. J Cheminform 2011;3:25 (1-14)
58. Pearson K. Mathematical contributions to the theory of evolution. III. Regression, heredity, and panmixia. Phil Trans R Soc Lond A 1896;187:253-318.
59. R Core Team R: A language and environment for statistical computing. version 2.11.1, 2010, R Foundation for Statistical Computing, Vienna, Austria 2012. Available from: Http://www. R-project.org [last accessed 3 Mar 2013]
60. Kendall M. A new measure of rank correlation. Biometrika 1938;30: 81-9.
61. Spearman C. General intelligence objectively determined and measured. Am J Psychol 1904;15:201-93.
62. Young DG. Computational drug design: A guide for computational and medicinal chemists. New Jersey: John Wiley & Sons Inc.; 2009. p. 175.
63. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71.
64. Katritzky AR, Mu L, Lobanov VS, Karelson M. Correlation of boiling points with molecular structure. 1. A training set of 298 diverse organics and a test set of 9 simple inorganics. J Phys Chem 1996;100:10400-7.
65. Kier LB, Hall LH. Molecular connectivity in structure-Activity analysis. New York: John Wiley & Sons Inc.; 1986. p. 226.
66. Kier LB. Inclusion of symmetry as a shape attribute in Kappa index analysis. Quant Struct Act Relat 1987;6:8-12.
67. Dearden JC. Quantitative structure-property relationships for prediction of boiling point, vapor pressure, and melting point. Environ Toxicol Chem 2003;23:1696-709.
68. Galvez J, Garcia R, Salabert MT, Soler R. Charge indexes. New topological descriptors. J Chem Inf Comput Sci 1994;34:520-52.
69. Barysz M, Jashari G, Lall RS, et al. Chemical applications of topology and graph theory. Amsterdam: Elsevier Holland; 1983: 222-30.
70. Moreau G, Broto P. The autocorrelation of a topological structure: A new molecular descriptor. Nouv J Chim 1980;4:359-60.
71. González MP, Caballero J, Helguera AM, et al. 2D Autocorrelation modelling of the inhibitory activity of cytokinin-derived cyclindependent kinase inhibitors. Bull Math Biol 2006;68:735-51.
72. Schuur J, Selzer P, Gasteiger J. The coding of the three-dimensional structure of molecules by molecular transforms and its application to structure-spectra correlations and studies of biological activity. J Chem Inf Comput Sci 1996;36:334-44.
73. Cheng Z, Zhang Y, Fu W. QSAR study of carboxylic acid derivatives as HIV-1 Integrase inhibitors. Eur J Med Chem 2010; 45:3970-80.
74. Yvonne Connolly Martin 3D QSAR: Current state, scope, and limitations. In: Kubinyi H, Folkers G, Martin YC, eds. 3D QSAR in drug design: Recent advances. Dordrecht: Kluwer/ESCOM Academic Publisher; 1998:9-11.
75. Chen Q, Higgs RE, Vieth M. Geometric accuracy of threedimensional molecular overlays. J Chem Inf Model 2006;46: 1996-2002.
76. Maestro, version 9.3, 2012, Schrodinger, LLC, New York, N.Y.
77. Cheng T, Wang Y, Bryant SH. Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules. Bioinformatics 2010;26:2881-8.
78. Ebalunode JO, Ouyang Z, Liang J, Zheng W. Novel approach to structure-based pharmacophore search using computational geometry and shape matching techniques. J Chem Inf Model 2008;48: 889-901.
79. Becker OM, Levy Y, Ravitz O. Flexibility, conformation spaces, and bioactivity. J Phys Chem B 2000;104:2123-35.
80. Chen H, Lyne PD, Giordanetto F, et al. On evaluating moleculardocking methods for pose prediction and enrichment factors. J Chem Inf Model 2006;46:401-15.
81. Discovery Studio Visualizer-Accelrys version 2.5 2009 San Diego, C.A.
82. Pacureanu L, Crisan L, Bora A, et al. In silico classification and virtual screening of maleimide derivatives using projection to latent structures discriminant analysis (PLS-DA) and hybrid docking. Monatsh Chem 2012;143:1559-73.